Showing 1331-1340 of 20878 results for "".
- New Compounds Identified for ROS1 G2032R Mutationhttps://reachmd.com/news/new-compounds-identified-for-ros1-g2032r-mutation/2485501/A recent computational study has identified four small molecules that may inhibit the crizotinib-resistant ROS1 G2032R mutation found in non-small-cell lung cancer (NSCLC). Resistance to ROS1-targeted therapies,
- Icotrokinra Maintains Psoriasis Responses With Continuous Treatmenthttps://reachmd.com/news/icotrokinra-maintains-psoriasis-responses-with-continuous-treatment/2485554/Continuous treatment with icotrokinra resulted in durable psoriasis control through one year, while treatment withdrawal was associated with rapid loss of response, according to “Maintenance of Response With Icotrokinra for the Treatment of Moderate-to-Severe Plaque Psoriasis: Results From the Ph
- Povorcitinib Improves Lesion Burden and Pain in Hidradenitis Suppurativahttps://reachmd.com/news/povorcitinib-improves-lesion-burden-and-pain-in-hidradenitis-suppurativa/2485551/Oral povorcitinib produced early and sustained improvements in lesion burden and pain in patients with moderate-to-severe hidradenitis suppurativa (HS), according to “Effect of Povorcitinib on Hidradenitis Suppurativa Lesions Through 24 Weeks in STOP-HS Trials,” a poster by Jennifer L. Hsiao, MD,
- ORKA-001 Phase 1 Data Support Potential Once-Yearly IL-23 Dosinghttps://reachmd.com/news/orka-001-phase-1-data-support-potential-once-yearly-il-23-dosing/2485550/A half-life–extended IL-23p19 monoclonal antibody demonstrated sustained pharmacokinetics and favorable tolerability that may support once-yearly dosing in plaque psoriasis, according to “Phase 1 Clinical Data of ORKA-001, a Novel Half-Life–Extended IL-23p19 Monoclonal Antibody,” a poster by Jame
- Dupilumab Produces Early and Sustained Improvements in CSU Activityhttps://reachmd.com/news/dupilumab-produces-early-and-sustained-improvements-in-csu-activity/2485548/Dupilumab produced early and sustained reductions in urticaria activity in patients with chronic spontaneous urticaria (CSU), according to “Dupilumab Provides Early and Sustained Improvement in Urticaria Activity in Patients With Chronic Spontaneous Urticaria,” a poster by Jonathan A. Bernstein,
- Advancements in Lab-Grown Corticospinal Neurons for ALS and Spinal Injury Researchhttps://reachmd.com/news/advancements-in-lab-grown-corticospinal-neurons-for-als-and-spinal-injury-research/2485521/New evidence demonstrates that corticospinal-like neurons can be generated in vitro with high subtype specificity and fidelity, providing a developmentally informed mod
- Transcranial Direct Current Stimulation: Evaluating Clinical Implications for Depression and Anxietyhttps://reachmd.com/news/transcranial-direct-current-stimulation-evaluating-clinical-implications-for-depression-and-anxiety/2485533/Frontal transcranial direct current stimulation (tDCS) acutely enhances executive function–related neural and behavioral performance in individuals with major depressive disorder and comorbid anxiety, but does not reduce—and may increase—physiological and neural markers of threat se
- Molecular Evolution of SARS-CoV-2 in Immunocompromised Patients: Clinical Insights and Management Strategieshttps://reachmd.com/news/molecular-evolution-of-sars-cov-2-in-immunocompromised-patients-clinical-insights-and-management-strategies/2485522/Replication‑competent SARS‑CoV‑2 persisted for months to years in three immunocompromised patients, driving intra‑host viral evolution and prompting reconsideration of surveillance and treatment strategies. The team performed detailed longitudinal virologic assessmen
- Electrical Impedance Tomography in Pediatric Extubation: New Findings and Implicationshttps://reachmd.com/news/electrical-impedance-tomography-in-pediatric-extubation-new-findings-and-implications/2485527/Electrical impedance tomography (EIT) detects real-time peri-extubation changes in lung physiology in critically ill children and provides detailed physiologic characterization of the immediate post-extubation period. This physiologic signal was captured in
- Mechanistic Insights into TP53 Inactivation and SCD1 Upregulation Driving Brain Metastasis in Breast Cancerhttps://reachmd.com/news/mechanistic-insights-into-tp53-inactivation-and-scd1-upregulation-driving-brain-metastasis-in-breast-cancer/2485448/TP53 loss and SCD1 upregulation are pervasive features of breast cancer brain metastasis and are linked to aggressive disease biology; TP53 inactivation is specifically associated with this clinical phenotype. In vivo, TP53 perturbation increased the capacity of tumor cells to colon